SINGAPORE, 14 APRIL 2022: Us2.ai, the Singapore-based medtech developers of FDA- cleared AI software that, for the first time ever, fully automates a complete echocardiography (heart ultrasound) report, today announced...
Curis (NASDAQ: CRIS) is the product of a three-way merger in 2000 of Pappas Capital portfolio company Reprogenesis with Creative Biomolecules and Ontogeny. The company was initially focused on regenerative medicine, but has evolved to become a leader in targeting signaling pathways – especially those involved in different cancers. The company’s so-called Hedgehog pathway inhibitor vismodegib is now being marketed in collaboration with Genentech.
Curis
Lexington, MA
NASDAQ
CRIS
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.